LEUKEMIA & LYMPHOMA

简称 LEUKEMIA LYMPHOMA ·ENGLAND ·出版周期 Monthly ·年均收录 272 篇

2.2

最新影响因子

7.40%

自引率

约66.66%

投稿难度

平均1.8月

审稿周期

期刊简介

LEUKEMIA & LYMPHOMA是一本国际性学术期刊，ISSN号为1042-8194，由英国出版商Taylor & Francis出版，出版地为英国，出版周期为月刊。该期刊的影响因子根据年份有所不同，近年约在2-3之间，属于SCI收录期刊，但具体中科院分区需查询最新数据，目前为非开放获取（OA）期刊。杂志主要聚焦白血病和淋巴瘤的基础与临床研究，涵盖病理机制、诊断技术、治疗方法和预后评估等领域，尤其关注血液系统恶性肿瘤的创新性研究。其发文特点包括原创研究论文、综述和病例报告，旨在促进血液学领域的学术交流。杂志质量中等偏上，审稿流程较为严格，但影响因子相对较低可能反映其学术影响力有限，投稿时需注意研究内容的创新性和临床相关性。总体而言，该期刊适合血液肿瘤领域的研究者投稿，但需结合自身研究目标和期刊定位权衡选择。

影响因子趋势

近期发表

Prognostic factors and survival in HHV8 positive diffuse large B cell lymphoma: a national cancer database analysis 2026-09-16

Letter to the editor regarding ‘Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan’ 2026-09-16

Beyond the gut: cutaneous manifestations and transformation in indolent T-cell lymphoma of the gastrointestinal tract 2026-09-17

Spontaneous regression of pharyngeal indeterminate dendritic cell tumor with KRAS and TP53 mutations 2026-09-13

Expanding access to leukemia specialists in the venetoclax era 2026-09-13

Adverse events, quality of life, and work impairment in patients with chronic myeloid leukemia (CML)—a survey of first- and second-line tyrosine kinase inhibitor (TKI) intolerance in the US 2026-09-13

Usefulness of 20-mm incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma: a single-center experience 2026-09-12

Optimized dosing of momelotinib in myelofibrosis through quantitative medicine: a clinical commentary 2026-09-11

Elevated expression of heme metabolism genes as a favorable biomarker in SF3B1 -mutated myelodysplastic neoplasms 2026-09-10

Surface expression of ROR1 across lymphoma cell lines identifies models for preclinical evaluation of ROR1-targeting antibody-drug conjugates 2026-09-07